A Multi-center Cohort Study of Hydatidiform Mole in China (CN-HM-01)
NCT ID: NCT07202728
Last Updated: 2025-10-02
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
1489 participants
OBSERVATIONAL
2025-07-09
2030-08-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study of Different Therapeutic Strategies in Hydatidiform Mole With Lung Nodule
NCT03785574
Clinical Study of HMPL-653 in Treatment of Advanced Malignant Solid Tumors and TGCT
NCT05277454
A Study of BL-M17D1 in Patients With Locally Advanced or Metastatic HER2 Positive/Lower Expression Gastrointestinal Cancer and Other Solid Tumors
NCT06500052
A Study of GNC-077 in Patients With Locally Advanced or Metastatic Gastrointestinal Tumors and Other Solid Tumors
NCT06755242
Clinical Study of GT201 in Combination With PD-1 Inhibitor for Advanced Head and Neck Tumors
NCT06190275
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Hydatidiform mole
This cohort aims to support the development of evidence-based precision management strategies and facilitate nationwide promotion of optimal care practices for molar pregnancy.
No intervention
No intervention
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
No intervention
No intervention
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Availability of complete medical records, including clinical and pathological data.
3. No evidence of myometrial invasion or metastasis.
4. Serum hCG levels normalized after uterine evacuation with at least 6 months of follow-up, OR diagnosed with postmolar gestational trophoblastic neoplasia (pGTN) during follow-up.
5. No history of psychiatric disorders, serious infectious diseases, or immune system diseases (such as systemic lupus erythematosus, myasthenia gravis, HIV infection, etc.).
6. Willing to participate in this study and sign the relevant informed consent form.
Exclusion Criteria
2. Loss to follow-up: Do not return to participating hospital for follow-up visits after uterine evacuation, or could not be contacted for subsequent monitoring of hCG changes.
3. Concomitant malignancies or autoimmune deficiency disorders (e.g., systemic lupus erythematosus, myasthenia gravis, HIV infection, etc.).
4. As determined by the investigator, the presence of medical, psychological, social, occupational, or other conditions that would violate the study protocol or impair the subject's ability to provide informed consent.
18 Years
60 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Peking Union Medical College Hospital
OTHER
Shengjing Hospital
OTHER
Hebei Medical University Third Hospital
OTHER
Hainan women and children medical center
UNKNOWN
Shenzhen Maternity & Child Healthcare Hospital
OTHER
Third Affiliated Hospital of Zhengzhou University
OTHER
Shanghai First Maternity and Infant Hospital
OTHER
International Peace Maternity and Child Health Hospital
OTHER
Shandong University
OTHER
First Affiliated Hospital of Zhejiang University
OTHER
The Affiliated Hospital of Qingdao University
OTHER
Gansu Provincial Maternity and Child-care Hospital/Gansu Provincial Central Hospital
UNKNOWN
Dalian women and children's medical group
UNKNOWN
Obstetrics & Gynecology Hospital of Fudan University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Xin Lu
Director of Chemotherapy Unit, Gynecologic Oncology Department, Obstetrics and Gynecology Hospital,
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Xin Lu, MD & PhD
Role: STUDY_CHAIR
Obstetrics & Gynecology Hospital of Fudan University
Yang Xiang, MD & PhD
Role: STUDY_CHAIR
Peking Union Medical College Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Gansu Province Maternal and Child Care Hospital
Lanzhou, Gansu, China
Shenzhen Maternity & Child Healthcare Hospital
Shenzhen, Guangdong, China
Hainan women and children medical center
Haikou, Hainan, China
Hebei Medical University Third Hospital
Shijiazhuang, Hebei, China
Third Affiliated Hospital of Zhengzhou University
Zhengzhou, Henan, China
Dalian Women and Children medical Center
Dalian, Liaoning, China
Shengjing Hospital of China Medical University
Shenyang, Liaoning, China
Center for Reproductive Medicine, Shandong University
Jinan, Shandong, China
The Affiliated Hospital of Qingdao University
Qingdao, Shandong, China
Shanghai First Maternity and Infant Hospital
Shanghai, Shandong, China
Obstetrics & Gynecology Hospital of Fudan University
Shanghai, Shanghai Municipality, China
First Affiliated Hospital of Zhejiang University
Hangzhou, Zhejiang, China
Peking Union Medical College Hospital
Beijing, , China
International Peace Maternity and Child Health Hospital
Shanghai, , China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2025-109
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.